Ignite Creation Date:
2025-12-24 @ 10:42 PM
Ignite Modification Date:
2026-03-04 @ 8:46 PM
Study NCT ID:
NCT03818035
Status:
COMPLETED
Last Update Posted:
2025-04-27
First Post:
2019-01-11
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2023-03-31', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D011565', 'term': 'Psoriasis'}], 'ancestors': [{'id': 'D017444', 'term': 'Skin Diseases, Papulosquamous'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000588857', 'term': 'guselkumab'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrialDisclosure@its.jnj.com', 'phone': '844-434-4210', 'title': 'GUIDE-Study Responsible Physician', 'organization': 'Janssen Research & Development LLC'}, 'certainAgreement': {'otherDetails': 'If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'As per change in the planned analysis Group 2d analysis was not performed, analysis of corresponding secondary endpoints has been postponed to avoid delay of study Part 2 analysis.'}}, 'adverseEventsModule': {'timeFrame': 'Part 1: Up to Week 28; Part 2: from Week 28 up to Week 72', 'description': 'Same event may appear as AE and serious adverse event (SAE), what is presented are distinct events. Event may be categorized as serious in 1 participant and as non-serious in another participant or 1 participant may have experienced both serious and non-serious event during study. Safety analysis population included all participants who were treated with at least one dose of study drug.', 'eventGroups': [{'id': 'EG000', 'title': 'Group 1: Guselkumab 100 mg', 'description': 'Participants with moderate to severe plaque-type psoriasis received guselkumab 100 milligrams (mg) subcutaneous (SC) injection at Weeks 0, 4, 12, and 20 in Part 1.', 'otherNumAtRisk': 880, 'deathsNumAtRisk': 880, 'otherNumAffected': 631, 'seriousNumAtRisk': 880, 'deathsNumAffected': 1, 'seriousNumAffected': 38}, {'id': 'EG001', 'title': 'Group 2a: Guselkumab 100 mg Q8W', 'description': 'Super responders (Psoriasis Area and Severity Index \\[PASI\\] score = 0 at Week 20 and Week 28) who completed study Part 1, were randomized to receive guselkumab 100 mg SC injection every 8 weeks (Q8W) dosing regimen starting at Week 28 till Week 60. Participants were followed from Week 28 till Week 68 or early termination prior to Week 68.', 'otherNumAtRisk': 148, 'deathsNumAtRisk': 148, 'otherNumAffected': 101, 'seriousNumAtRisk': 148, 'deathsNumAffected': 0, 'seriousNumAffected': 7}, {'id': 'EG002', 'title': 'Group 2b: Guselkumab 100 mg Q16W', 'description': 'Super responders (PASI score = 0 at Week 20 and Week 28) who completed study Part 1, were randomized to receive guselkumab 100 mg SC injection every 16 weeks (Q16W) dosing regimen at Weeks 36 and 52. To maintain the study blind, participants were administered placebo SC injection at Weeks 28, 44 and 60. Participants were followed from Week 28 till Week 68 or early termination prior to Week 68.', 'otherNumAtRisk': 149, 'deathsNumAtRisk': 149, 'otherNumAffected': 103, 'seriousNumAtRisk': 149, 'deathsNumAffected': 0, 'seriousNumAffected': 6}, {'id': 'EG003', 'title': 'Group 2c: Guselkumab 100 mg Q8W', 'description': 'Non-super responders (PASI score greater than \\[\\>\\] 0 at Week 20 and/or Week 28) who completed study Part 1 continued to receive guselkumab 100 mg SC injection Q8W dosing regimen starting at Week 28 till Week 60. Participants were followed from Week 28 till Week 68 or early termination prior to Week 68.', 'otherNumAtRisk': 525, 'deathsNumAtRisk': 525, 'otherNumAffected': 367, 'seriousNumAtRisk': 525, 'deathsNumAffected': 1, 'seriousNumAffected': 33}], 'otherEvents': [{'term': 'Iron Deficiency Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Lymphadenitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Lymphadenopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Lymphopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Splenomegaly', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Spontaneous Haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Thrombocytosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Angina Pectoris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Aortic Valve Incompetence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Aortic Valve Sclerosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Aortic Valve Stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Atrial Fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cardiac Failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cardiac Perfusion Defect', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cardiovascular Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Coronary Artery Disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Heart Valve Incompetence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Left Ventricular Hypertrophy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Mitral Valve Incompetence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Myocardial Infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Sinus Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Supraventricular Extrasystoles', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Epidermal Naevus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Congenital, familial and genetic disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': "Gilbert's Syndrome", 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Congenital, familial and genetic disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Phimosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Congenital, familial and genetic disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Conductive Deafness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Deafness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ear Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Excessive Cerumen Production', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypoacusis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Sudden Hearing Loss', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tinnitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Androgen Deficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Goitre', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hyperprolactinaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hyperthyroidism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypothyroidism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Borderline Glaucoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Chalazion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Conjunctival Irritation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Conjunctivitis Allergic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dry Eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Eczema Eyelids', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Eye Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Glaucoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Keratitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Lacrimation Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ocular Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ocular Hyperaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ocular Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Optic Nerve Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Retinal Haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ulcerative Keratitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Vision Blurred', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Visual Acuity Reduced', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abdominal Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abdominal Distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abdominal Hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abdominal Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abdominal Pain Lower', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abdominal Pain Upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 9}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Anal Fissure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Aphthous Ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dental Caries', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dental Necrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 24}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 13}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Diverticulum Intestinal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dry Mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dysphagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Epigastric Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Erosive Duodenitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Faeces Soft', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Flatulence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gastric Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gastrointestinal Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gastrointestinal Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gastrointestinal Polyp Haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gastrooesophageal Reflux Disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gingival Bleeding', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gingival Cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Haematochezia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Haemorrhoids', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Haemorrhoids Thrombosed', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hiatus Hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Inguinal Hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Large Intestine Polyp', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Paraesthesia Oral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Rectal Haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tongue Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Toothache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Umbilical Hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Adverse Drug Reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Application Site Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Chest Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Chest Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Chills', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Drug Ineffective', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Foreign Body Reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'General Physical Health Deterioration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Impaired Healing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Influenza Like Illness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Injection Site Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 5}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Injection Site Haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Injection Site Hypersensitivity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Injection Site Induration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Injection Site Oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Injection Site Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Injection Site Paraesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Injection Site Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Injection Site Reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 5}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Injection Site Scar', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Injection Site Swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Localised Oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Oedema Peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Peripheral Swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Temperature Intolerance', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Vaccination Site Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Vaccination Site Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Biliary Colic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hepatic Steatosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hyperbilirubinaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Allergy to Arthropod Bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Anaphylactic Reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Contrast Media Reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Food Allergy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Mite Allergy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Seasonal Allergy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abscess Jaw', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abscess Limb', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abscess Oral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Acarodermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Acne Pustular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Acute Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Anal Abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Bacterial Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Balanitis Candida', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Body Tinea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Borrelia Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 12}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 10}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Bronchitis Bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Candida Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cervicitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Chronic Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Conjunctivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Coronavirus Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Covid-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 13}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Diabetic Foot Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Diverticulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ear Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Eczema Infected', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Enteritis Infectious', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Epididymitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Erysipelas', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Erythema Migrans', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Folliculitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Fungal Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Fungal Skin Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Furuncle', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gastric Ulcer Helicobacter', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 18}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gastroenteritis Viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gastrointestinal Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 12}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 9}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gastrointestinal Viral Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Genital Herpes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Genital Infection Bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Genital Infection Fungal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gingivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hantaviral Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Helicobacter Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Herpes Simplex', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Herpes Virus Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Herpes Zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hordeolum', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Infected Bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Infected Cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Infected Dermal Cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Infected Skin Ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Infectious Mononucleosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Infective Glossitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Laryngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Localised Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Lyme Disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Malassezia Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Mastitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nail Bed Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nasal Herpes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 214}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 26}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 23}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 97}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Oesophageal Candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Onychomycosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Oral Candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Oral Fungal Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Oral Herpes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Otitis Externa', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Otitis Media', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Otitis Media Viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Paronychia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Parotitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pelvic Inflammatory Disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Periodontitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Peritonsillar Abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Postoperative Wound Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pulpitis Dental', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pustule', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pyelitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pyelonephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Respiratory Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Rhinitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Root Canal Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Scarlet Fever', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Bacterial Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Candida', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Staphylococcal Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Subcutaneous Abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tinea Cruris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tinea Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tinea Manuum', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tinea Pedis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tinea Versicolour', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tonsillitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 12}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tonsillitis Bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tooth Abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tooth Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Upper Respiratory Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 22}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Urethritis Gonococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Urinary Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Urinary Tract Infection Bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Vaginal Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Viral Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Viral Upper Respiratory Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Vulvovaginal Mycotic Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Wound Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ankle Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Arthropod Bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Arthropod Sting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Bone Contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Burns Second Degree', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Burns Third Degree', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Chillblains', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Clavicle Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Corneal Abrasion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Epicondylitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Eye Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Fibula Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Foot Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Foreign Body in Eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Fractured Coccyx', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hand Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Heat Stroke', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Human Bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Humerus Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Inappropriate Schedule of Product Administration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 14}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Incision Site Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Incomplete Spinal Fusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Joint Capsule Rupture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Joint Dislocation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Joint Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ligament Rupture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ligament Sprain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Limb Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Lower Limb Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Lumbar Vertebral Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Meniscus Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 5}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Muscle Rupture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Muscle Strain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Post Procedural Haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Post Procedural Hypothyroidism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Post Procedural Swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Post-Traumatic Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Procedural Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Procedural Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Road Traffic Accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Abrasion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Laceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Sunburn', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tendon Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tendon Rupture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Thermal Burn', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tooth Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Traumatic Haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Urinary Retention Postoperative', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Vaccination Complication', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 6}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Wound', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Wrist Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Alanine Aminotransferase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Aortic Bruit', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Aspartate Aminotransferase Abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Aspartate Aminotransferase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Basophil Count Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Bilirubin Conjugated Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Bilirubin Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Bilirubin Unconjugated Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Cholesterol Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Creatine Phosphokinase Abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Creatine Phosphokinase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 20}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 8}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Creatinine Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Glucose Decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Glucose Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Lactate Dehydrogenase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Potassium Abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Potassium Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Pressure Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Triglycerides Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Urea Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blood Uric Acid Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cardiac Murmur', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gamma-Glutamyltransferase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 4}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Haematocrit Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Heart Rate Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hepatic Enzyme Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Lipase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Lipids Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Liver Function Test Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Lymphocyte Count Decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Lymphocyte Morphology Abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Neutrophil Count Decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Neutrophil Count Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Platelet Count Decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Platelet Count Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Prostatic Specific Antigen Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Spermatozoa Abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Streptococcus Test Positive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Transaminases Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tri-Iodothyronine Free Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Weight Decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Weight Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'White Blood Cell Count Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Decreased Appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Diabetes Mellitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dyslipidaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Fat Intolerance', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gout', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypercholesterolaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hyperglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hyperlipidaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypertriglyceridaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hyperuricaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypokalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypovitaminosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Obesity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Selenium Deficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Type 2 Diabetes Mellitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Vitamin B12 Deficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Vitamin D Deficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Weight Fluctuation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 41}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 29}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Arthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Arthropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Back Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 26}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 8}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 13}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Bursitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Chondropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Enthesopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Exostosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Fibromyalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Flank Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Groin Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Intervertebral Disc Degeneration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Intervertebral Disc Protrusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 6}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Joint Stiffness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Joint Swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Limb Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Muscle Tightness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Muscular Weakness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Musculoskeletal Chest Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Musculoskeletal Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Musculoskeletal Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Musculoskeletal Stiffness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Myositis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Neck Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nodal Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pain in Extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 6}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Periarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Plantar Fasciitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Polymyalgia Rheumatica', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pseudarthrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Psoriatic Arthropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 6}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Rotator Cuff Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Sacral Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Scoliosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Spinal Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Spinal Stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Synovitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tendon Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tendonitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Trigger Finger', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Acanthoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Anogenital Warts', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Basal Cell Carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Benign Hepatic Neoplasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Benign Neoplasm of Adrenal Gland', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Benign Neoplasm of Eyelid', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dysplastic Naevus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Fibroadenoma of Breast', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Fibroma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Fibrous Histiocytoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Lipoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Melanocytic Naevus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Osteoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Prostate Cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Seborrhoeic Keratosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Papilloma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Squamous Cell Carcinoma of Skin', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Transitional Cell Carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Anosmia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Carpal Tunnel Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cervicobrachial Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cognitive Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cubital Tunnel Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Disturbance in Attention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dizziness Postural', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dysaesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Facial Paralysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Gliosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Head Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 79}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 9}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 29}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypoaesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Migraine', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Migraine with Aura', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nerve Compression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Neuritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Neuropathy Vitamin B6 Deficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Orthostatic Intolerance', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Paraesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Peripheral Nerve Lesion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Post Herpetic Neuralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Precerebral Arteriosclerosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Presyncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pseudoradicular Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Radiculopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Restless Legs Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Sciatica', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Thoracic Outlet Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Thoracic Radiculopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tremor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pregnancy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Pregnancy, puerperium and perinatal conditions', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Burnout Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Depressive Symptom', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Panic Attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Personality Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Restlessness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Sleep Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Sleep Disorder Due to A General Medical Condition', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Stress', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Suicidal Behaviour', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dysuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Haematuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nephrolithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nocturia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Urethral Stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Urinary Incontinence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Benign Prostatic Hyperplasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dysmenorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Endometriosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Erectile Dysfunction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Haemorrhagic Ovarian Cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Heavy Menstrual Bleeding', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Menopausal Symptoms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Menstruation Irregular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ovarian Cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Polycystic Ovaries', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Prostatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Prostatomegaly', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pruritus Genital', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Testicular Torsion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Vulvovaginal Dryness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Allergic Respiratory Symptom', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Allergic Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Asthma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Catarrh', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 10}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dyspnoea Exertional', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Emphysema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Epistaxis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypersensitivity Pneumonitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Increased Upper Airway Secretion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Larynx Irritation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nasal Congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nasal Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nasal Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nasal Septum Deviation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Oropharyngeal Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 12}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 5}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Painful Respiration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pleurisy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Productive Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Rhinitis Allergic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Rhinorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Sleep Apnoea Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Throat Irritation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tonsillar Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Upper Airway Obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Acne', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Actinic Keratosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Alopecia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Angioedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Blister', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Chloasma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dermal Cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dermatitis Allergic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dermatitis Contact', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dermatitis Psoriasiform', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Drug Eruption', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dry Skin', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Dyshidrotic Eczema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Eczema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 11}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Eczema Asteatotic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Eczema Nummular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Erythema Nodosum', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Erythrodermic Psoriasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hyperhidrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 3}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hyperkeratosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Intertrigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Koebner Phenomenon', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nail Dystrophy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nail Psoriasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 5}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Night Sweats', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Perioral Dermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Photosensitivity Reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pityriasis Rosea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Polymorphic Light Eruption', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Prurigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 5}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Psoriasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 8}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Rash Erythematous', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Rash Pruritic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Rosacea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Seborrhoeic Dermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Burning Sensation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Fissures', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Fragility', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Induration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Irritation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Maceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Mass', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Texture Abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Skin Ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Solar Dermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Stasis Dermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Toxic Skin Eruption', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Urticaria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 7}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Urticaria Contact', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Urticaria Physical', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Vitiligo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Deep Vein Thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Extremity Necrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Flushing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hot Flush', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 48}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 31}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypertensive Crisis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypertensive Urgency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Peripheral Arterial Occlusive Disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Peripheral Venous Disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Thrombophlebitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Varicose Vein', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'White Coat Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}], 'seriousEvents': [{'term': 'Splenic Haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Acute Coronary Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Acute Myocardial Infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Arteriosclerosis Coronary Artery', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cardiac Failure Chronic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Coronary Artery Disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Myocardial Infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Myocarditis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abdominal Hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abdominal Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Chest Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cholecystitis Chronic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cholestasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Anaphylactic Reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Autoimmune Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypersensitivity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abscess of External Auditory Meatus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Anal Abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Appendicitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Bacterial Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Chronic Tonsillitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Covid-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Diverticulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Erysipelas', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Infectious Mononucleosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Peritonsillar Abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Post Procedural Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Staphylococcal Bacteraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tooth Abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Abdominal Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ankle Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Bone Contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cartilage Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Clavicle Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Foot Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Humerus Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ligament Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ligament Rupture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Lumbar Vertebral Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pelvic Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Post Procedural Haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Radius Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Rib Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Road Traffic Accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Traumatic Liver Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Obesity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Type 2 Diabetes Mellitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Bursitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Fibromyalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Intervertebral Disc Protrusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Muscular Weakness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Myositis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Rotator Cuff Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Spinal Stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Basal Cell Carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Benign Hepatic Neoplasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Colorectal Cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Prostate Cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Squamous Cell Carcinoma of Skin', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Transitional Cell Carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Tumour Haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cerebral Infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Cerebrovascular Accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Nerve Compression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Polyneuropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Presyncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pseudoradicular Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Suicidal Behaviour', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Ovarian Cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Asphyxia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypersensitivity Pneumonitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Pleurisy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Psoriasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Aortic Aneurysm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Extremity Necrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}, {'term': 'Hypertensive Urgency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 880, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 149, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 525, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 24.1'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Group 2a and Group 2b: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index (PASI) Score Less Than (<) 3 at Week 68', 'denoms': [{'units': 'Participants', 'counts': [{'value': '148', 'groupId': 'OG000'}, {'value': '149', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Group 2a: Guselkumab 100 mg Q8W', 'description': 'Super responders (Psoriasis Area and Severity Index \\[PASI\\] score = 0 at Week 20 and Week 28) who completed study Part 1, were randomized to receive guselkumab 100 mg SC injection every 8 weeks (Q8W) dosing regimen starting at Week 28 till Week 60. Participants were followed from Week 28 till Week 68 or early termination prior to Week 68.'}, {'id': 'OG001', 'title': 'Group 2b: Guselkumab 100 mg Q16W', 'description': 'Super responders (PASI score = 0 at Week 20 and Week 28) who completed study Part 1, were randomized to receive guselkumab 100 mg SC injection every 16 weeks (Q16W) dosing regimen at Weeks 36 and 52. To maintain the study blind, participants were administered placebo SC injection at Weeks 28, 44 and 60. Participants were followed from Week 28 till Week 68 or early termination prior to Week 68.'}], 'classes': [{'categories': [{'measurements': [{'value': '92.6', 'groupId': 'OG000', 'lowerLimit': '88.0', 'upperLimit': '95.8'}, {'value': '91.9', 'groupId': 'OG001', 'lowerLimit': '87.3', 'upperLimit': '95.3'}]}]}], 'analyses': [{'pValue': '0.0013', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Risk Difference (RD)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '-0.6', 'ciLowerLimit': '-5.7', 'ciUpperLimit': '4.5', 'statisticalMethod': 'Wald Z-test', 'nonInferiorityType': 'NON_INFERIORITY', 'nonInferiorityComment': "One-sided two-group normal approximation Wald Z-test with Mantel-Haenszel stratum weights for 'disease duration' to test for non-inferiority of 100 mg q16w to 100 mg q8w with non-inferiority margin of 10%. Stratified analysis results are reported."}], 'paramType': 'NUMBER', 'timeFrame': 'Week 68', 'description': 'Percentage of participants who achieved an absolute PASI \\<3 at Week 68 were reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the body surface area involved, which translates to a numeric score that ranged from 0 (indicated no involvement) to 6 (90 percentage \\[%\\]-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis.', 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population for Part 2 (Group 2a and Group 2b) included all randomized participants at week 28. Here, 'N' (Overall number of participants) signifies participants who continued study treatment in Part 2 with blinded study drug (randomized Groups 2a and 2b) or with open label study drug (Group 2c)."}, {'type': 'SECONDARY', 'title': 'Time to Improvement From Baseline (Week 0) in PASI Score', 'timeFrame': 'Group 1: Week 0 up to Week 28; Group 2a, 2b, 2c: Week 28 up to Week 68', 'description': 'Time to improvement from baseline in PASI (PASI 75/90/100 response and absolute PASI score =0) for participants with short disease duration (SDD) (less than or equal to \\[\\<=\\] 2 years) and longer disease duration (LDD) (greater than \\[\\>\\] 2 years) was reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. PASI 75/90/100 responders were defined as participants with \\>= 75%, \\>= 90%, 100% improvement in PASI respectively.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Group 1, Group 2a, Group 2b, Group 2c, Group 3a and Group 3b: Percentage of Participants Who Achieved an Absolute PASI Score of 0, <=1 and <3 at Weeks 20, 28, 68, 116, 164 and 120', 'timeFrame': 'Weeks 20, 28, 68, 116, 164 and 120', 'description': 'Percentage of participants with short (\\<=2 years) and longer (\\>2 years) disease duration who achieved an absolute PASI Score of 0, \\<=1 and less than (\\<) 3 will be reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Group 3a and Group 3b: Percentage of Participants Who Retain Disease Control (Absolute PASI Score < 3)', 'timeFrame': 'Week 68 up to Week 116', 'description': 'Percentage of participants who retain disease control (that is, absolute PASI score \\<3 from week 68 through week 116 for participants with short (\\<= 2 years) and longer (\\>2 years) disease duration will be reported. Control of disease was defined as participants with a PASI score \\<3. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Group 1, Group 2a, Group 2b, Group 2c, Group 3a and Group 3b: Percentage of Participants Who Achieve a PASI 75/90/100 Response at Weeks 20, 28, 68, 116, 164, and 220', 'timeFrame': 'Weeks 20, 28, 68, 116, 164, and 220', 'description': 'Percentage of participants who achieved PASI 75/90/100 response were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. PASI 75 responders were defined as participants with \\>= 75% improvement in PASI from baseline. PASI 90 responders were defined as participants with \\>= 90% improvement in PASI from baseline. PASI 100 responders were defined as participants with 100% improvement in PASI from baseline.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Group 3a and Group 3b: Time to Loss of Disease Control (Absolute PASI Score >5) After Treatment Withdrawal', 'timeFrame': 'Week 68 up to Week 220', 'description': 'Time to loss of disease control (absolute PASI score \\>5) after treatment withdrawal beyond Week 68 up to Week 116 were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Group 1: Percentage of Participants With an Absolute PASI Score = 0 at Weeks 12, 16, 20 and 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '880', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Group 1: Guselkumab 100 mg', 'description': 'Participants with moderate to severe plaque-type psoriasis received guselkumab 100 milligrams (mg) subcutaneous (SC) injection at Weeks 0, 4, 12, and 20 in Part 1.'}], 'classes': [{'title': 'Week 12', 'categories': [{'measurements': [{'value': '17.8', 'groupId': 'OG000'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '29.0', 'groupId': 'OG000'}]}]}, {'title': 'Week 20', 'categories': [{'measurements': [{'value': '39.4', 'groupId': 'OG000'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '44.4', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 12, 16, 20 and 28', 'description': 'Percentage of participants with an absolute PASI score = 0 at Weeks 12, 16, 20 and 28 were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population included all randomized participants.'}, {'type': 'SECONDARY', 'title': 'Group 1, Group 2a, Group 2b, Group 2c, Group 3a, Group 3b and Group 3c: Change From Baseline (Week 0) in Dermatology Life Quality Index (DLQI) Score at Weeks 28, 68, 116, 164 and 220', 'timeFrame': 'Baseline (Week 0), Weeks 28, 68, 116, 164 and 220', 'description': "Change from baseline (Week 0) in DLQI score at Weeks 28, 68, 116, 164 and 220 will be reported. DLQI was a 10-item instrument questionnaire designed to assess the impact of the disease on a participant's quality of life. Each question was evaluated on a 4-point scale ranged from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.", 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Group 1, Group 2a, Group 2b, Group 2c, Group 3a, Group 3b and Group 3c: Percentage of Participants Who Achieved a DLQI Score 0/1 and <5', 'timeFrame': 'Weeks 28, 68, 116, 164 and 220', 'description': "Percentage of participants who achieved a DLQI score 0/1 and \\<5 will be reported. DLQI was a 10-item instrument questionnaire designed to assess the impact of the disease on a participant's quality of life. Each question was evaluated on a 4-point scale ranged from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.", 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Groups 1, 2a, 2b, 2c, 2d, 3a, 3b, and 3c: Percent Change From Baseline (Week 0) in Psoriasis- Affected Body Surface Area (BSA) at Weeks 12, 28, 52, 68, 80, 104, 116, 140, 164, 188, 212 and 220', 'timeFrame': 'Baseline (Week 0), Weeks 12, 28, 52, 68, 80, 104, 116, 140, 164, 188, 212 and 220', 'description': 'Change from baseline in the psoriasis affected BSA (%) at Weeks 12, 28, 52, 68, 80, 104, 116, 140, 164, 188, 212 and 220 will be reported. The percentage of the psoriasis-affected BSA percentage is a system used for assessing the severity of psoriasis. The plaque coverage is estimated using the rule of palm (1 palm of the hand = 1% BSA).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Groups 1, 2a, 2b, 2c, 3a and 3b: Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis-Quality of Life (NAPPA-QOL) at Weeks 28, 68, 116, 164 and 220', 'timeFrame': 'Baseline (Week 0), 28, 68, 116, 164 and 220', 'description': 'Change from baseline in NAPPA-QOL at Weeks 28, 68, 116, 164 and 220 will be reported. The NAPPA was an instrument for assessing clinical and patient-reported outcomes in nail psoriasis. NAPPA-QOL was a 20-item nail-specific QoL questionnaire covering past week. Signs, stigma and everyday life were rated on a 5-point scale, ranged from 0 (no suffering) to 4 (high suffering). A global score was computed by averaging all items which ranged from 0 (no suffering) to 4 (high suffering). A decrease in NAPPA QoL score indicated improvement.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Groups 1, 2a, 2b, 2c, 3a, and 3b: Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis- Patient Benefit Index (NAPPA-PBI) at Weeks 28, 68, 116, 164 and 220', 'timeFrame': 'Baseline (Week 0), Weeks 28, 68, 116, 164 and 220', 'description': 'Change from baseline in NAPPA-PBI at Weeks 28, 68, 116, 164 and 220 will be reported. The NAPPA was an instrument for assessing clinical and patient-reported outcomes in nail psoriasis. NAPPA-PBI was a 24-item questionnaire to assess participant-defined needs before and participant-rated benefits after treatment. The answers were given on a scale from 0 to 4, and a global score was calculated as follows: Each benefit item was multiplied with the respective importance item, and the product is divided by the sum of all importance items. The results were summed up over all items. The resulting global score ranged from 0 (no benefit) to 4 (highest possible benefit). Higher score indicated more benefit.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Groups 1, 2a, 2b, 2c, 3a and 3b: Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis- Clinical (NAPPA-CLIN) at Weeks 28, 68, 116, 164 and 220', 'timeFrame': 'Baseline (Week 0), Weeks 28, 68, 116, 164 and 220', 'description': 'Change from baseline in NAPPA-CLIN at Weeks 28, 68, 116 164, and 220 will be reported. The NAPPA is an instrument for assessing clinical and patient-reported outcomes in nail psoriasis. NAPPA-CLIN is an instrument used by the physician to assess the least and the worst involved nail of both hands or both feet with scores ranging from 0 (no involvement) to 16 (worst involvement). A higher score indicated a worst involvement.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Group 1, Group 2a, Group 2b, Group 2c, Group 3a and Group 3b: Change From Baseline (Week 0) in the Signs and Symptoms Aggregate Scores of the Psoriasis Symptoms and Signs Diary (PSSD) at Weeks 28, 68, 116, 164 and 220', 'timeFrame': 'Baseline (Week 0), Weeks 28, 68, 116, 164 and 220', 'description': 'Change from baseline (Week 0) in the signs and symptoms aggregate scores of the PSSD at Weeks 28, 68, 116, 164 and 220 will be reported. The PSSD was a questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a participant self-administered outcomes instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores each ranging from 0 to 100 were derived: the psoriasis symptom score and the psoriasis sign score. A higher score indicated more severe disease. A change of \\>= 40 points in PSSD symptom score or sign score, and a \\>= 3-point change in individual PSSD item scale scores will be defined as clinically meaningful change (response).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Group 2a, Group 2b and Group 2c: Percentage of Participants Who Achieved a PSSD Sign Score = 0 at Week 68 in Participants With a PSSD Sign Score >= 1 at Week 28', 'timeFrame': 'Week 68', 'description': 'Percentage of participants who achieved a PSSD sign score = 0 at Week 68 in participants with a PSSD sign score \\>= 1 at Week 28 will be reported. The PSSD was a questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a participant self-administered outcomes instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores each ranging from 0 to 100 were derived: the psoriasis symptom score and the psoriasis sign score. A higher score indicated more severe disease. A change of \\>= 40 points in PSSD symptom score or sign score, and a \\>= 3-point change in individual PSSD item scale scores will be defined as clinically meaningful change (response).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Group 1, Group 2a, Group 2b and Group 2c: Relationship Between Trough Serum Concentration and Efficacy or Serum Biomarker Level', 'timeFrame': 'Up to Week 80', 'description': 'The potential association between trough serum guselkumab concentration and efficacy or serum biomarker level will be analyzed by immunoassays. For the analyses the trough serum guselkumab concentration will be set into relation with the efficacy (e.g. PASI response) or with serum biomarker (e.g. serum IL-17A, IL-17F, IL-22) concentration. Guselkumab and all biomarker concentrations will be measured in the unit of picogram/milliliter (pg/mL). In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Group 2a and Group 2b: Relationship Between Trough Serum Guselkumab Levels at Weeks 20, 28, 36 and 68 and Achieving PASI Score <3 at Week 68', 'timeFrame': 'Weeks 20, 28, 36, 68', 'description': 'The potential association between trough serum guselkumab levels at weeks 20, 28, 36 and 68 and achieving a PASI score \\<3 at Week 68 will be analyzed. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicated more severe disease.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Group 2d and Group 3c: Percentage of Participants Who Were Re-Treated Due to Loss of Disease Control (PASI >5) and Regain Control of Disease (PASI <3) 24 Weeks After Start of Re-Treatment', 'timeFrame': 'Start of re-treatment up to 24 weeks', 'description': 'Percentage of participants who were re-treated due to loss of disease control (PASI \\>5) and regain control of disease (PASI \\<3) 24 Weeks after start of re-treatment will be reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to numeric score that ranged from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Group 1, Group 2a, Group 2b, Group 2c, Group 2d, Group 3a, Group 3b, and Group 3c: Number of Participants With Adverse Events as a Measure of Safety and Tolerability', 'timeFrame': 'Up to Week 220', 'description': 'An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}, {'type': 'SECONDARY', 'title': 'Group 1, Group 2a, Group 2b, Group 2c, Group 2d, Group 3a, Group 3b and Group 3c): Number of Participants With Clinically Significant Laboratory Abnormalities', 'timeFrame': 'Week 220', 'description': 'Number of participants with laboratory abnormalities (hematology, serum chemistry and serology) were reported.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants', 'anticipatedPostingDate': '2026-01'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Group 1: Guselkumab 100 mg', 'description': 'Participants with moderate to severe plaque-type psoriasis received guselkumab 100 milligrams (mg) subcutaneous (SC) injection at Weeks 0, 4, 12, and 20 in Part 1.'}, {'id': 'FG001', 'title': 'Group 2a: Guselkumab 100 mg Q8W', 'description': 'Super responders (Psoriasis Area and Severity Index \\[PASI\\] score = 0 at Week 20 and Week 28) who completed study Part 1, were randomized to receive guselkumab 100 mg SC injection every 8 weeks (Q8W) dosing regimen starting at Week 28 till Week 60. Participants were followed from Week 28 till Week 68 or early termination prior to Week 68.'}, {'id': 'FG002', 'title': 'Group 2b: Guselkumab 100 mg Q16W', 'description': 'Super responders (PASI score = 0 at Week 20 and Week 28) who completed study Part 1, were randomized to receive guselkumab 100 mg SC injection every 16 weeks (Q16W) dosing regimen at Weeks 36 and 52. To maintain the study blind, participants were administered placebo SC injection at Weeks 28, 44 and 60. Participants were followed from Week 28 till Week 68 or early termination prior to Week 68.'}, {'id': 'FG003', 'title': 'Group 2c: Guselkumab 100 mg Q8W', 'description': 'Non-super responders (PASI score greater than \\[\\>\\] 0 at Week 20 and/or Week 28) who completed study Part 1 continued to receive guselkumab 100 mg SC injection Q8W dosing regimen starting at Week 28 till Week 60. Participants were followed from Week 28 till Week 68 or early termination prior to Week 68.'}], 'periods': [{'title': 'Part 1 (Up to 28 Weeks)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '880'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '823'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '57'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Adverse Event - Worsening of Psoriasis', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Adverse Event - Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '16'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Non-Compliance with Study Drug', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '7'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}]}, {'title': 'Part 2 (Week 28 to Week 68)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'comment': 'Only eligible participants from Part 1, were randomized into Part 2.', 'groupId': 'FG001', 'numSubjects': '148'}, {'comment': 'Only eligible participants from Part 1, were randomized into Part 2.', 'groupId': 'FG002', 'numSubjects': '150'}, {'comment': 'Only eligible participants from Part 1, entered into Part 2.', 'groupId': 'FG003', 'numSubjects': '525'}]}, {'type': 'Treated', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '148'}, {'groupId': 'FG002', 'numSubjects': '149'}, {'groupId': 'FG003', 'numSubjects': '525'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '137'}, {'groupId': 'FG002', 'numSubjects': '142'}, {'groupId': 'FG003', 'numSubjects': '496'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '11'}, {'groupId': 'FG002', 'numSubjects': '8'}, {'groupId': 'FG003', 'numSubjects': '29'}]}], 'dropWithdraws': [{'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '4'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '6'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '9'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '8'}]}, {'type': 'Other Adverse Events', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '7'}]}, {'type': 'Subject Started Retreatment Phase Within Study Part 2', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '880', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Group 1: Guselkumab 100 mg', 'description': 'Participants with moderate to severe plaque-type psoriasis received guselkumab 100 milligrams (mg) subcutaneous (SC) injection at Weeks 0, 4, 12, and 20 in Part 1.'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '14', 'groupId': 'BG000'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '803', 'groupId': 'BG000'}]}, {'title': '>=65 years', 'measurements': [{'value': '63', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '42.5', 'spread': '14.7', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '260', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '620', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Asian', 'categories': [{'measurements': [{'value': '8', 'groupId': 'BG000'}]}]}, {'title': 'Black', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}]}]}, {'title': 'White', 'categories': [{'measurements': [{'value': '859', 'groupId': 'BG000'}]}]}, {'title': 'More than one race', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}]}]}, {'title': 'Unknown or Not Reported', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}]}]}, {'title': 'Other', 'categories': [{'measurements': [{'value': '7', 'groupId': 'BG000'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'FRANCE', 'categories': [{'measurements': [{'value': '52', 'groupId': 'BG000'}]}]}, {'title': 'GERMANY', 'categories': [{'measurements': [{'value': '828', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Intent-to-treat (ITT) population for Part 1 included all participants who were treated with at least one dose of study in Part 1.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-06-14', 'size': 4585474, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2023-03-06T07:21', 'hasProtocol': True}, {'date': '2023-02-14', 'size': 1915487, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2023-03-06T07:21', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 880}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-02-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-04', 'completionDateStruct': {'date': '2025-01-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-04-24', 'studyFirstSubmitDate': '2019-01-11', 'resultsFirstSubmitDate': '2023-03-06', 'studyFirstSubmitQcDate': '2019-01-23', 'lastUpdatePostDateStruct': {'date': '2025-04-27', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2023-04-18', 'studyFirstPostDateStruct': {'date': '2019-01-28', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2023-05-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-03-07', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Group 2a and Group 2b: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index (PASI) Score Less Than (<) 3 at Week 68', 'timeFrame': 'Week 68', 'description': 'Percentage of participants who achieved an absolute PASI \\<3 at Week 68 were reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the body surface area involved, which translates to a numeric score that ranged from 0 (indicated no involvement) to 6 (90 percentage \\[%\\]-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis.'}], 'secondaryOutcomes': [{'measure': 'Time to Improvement From Baseline (Week 0) in PASI Score', 'timeFrame': 'Group 1: Week 0 up to Week 28; Group 2a, 2b, 2c: Week 28 up to Week 68', 'description': 'Time to improvement from baseline in PASI (PASI 75/90/100 response and absolute PASI score =0) for participants with short disease duration (SDD) (less than or equal to \\[\\<=\\] 2 years) and longer disease duration (LDD) (greater than \\[\\>\\] 2 years) was reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. PASI 75/90/100 responders were defined as participants with \\>= 75%, \\>= 90%, 100% improvement in PASI respectively.'}, {'measure': 'Group 1, Group 2a, Group 2b, Group 2c, Group 3a and Group 3b: Percentage of Participants Who Achieved an Absolute PASI Score of 0, <=1 and <3 at Weeks 20, 28, 68, 116, 164 and 120', 'timeFrame': 'Weeks 20, 28, 68, 116, 164 and 120', 'description': 'Percentage of participants with short (\\<=2 years) and longer (\\>2 years) disease duration who achieved an absolute PASI Score of 0, \\<=1 and less than (\\<) 3 will be reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.'}, {'measure': 'Group 3a and Group 3b: Percentage of Participants Who Retain Disease Control (Absolute PASI Score < 3)', 'timeFrame': 'Week 68 up to Week 116', 'description': 'Percentage of participants who retain disease control (that is, absolute PASI score \\<3 from week 68 through week 116 for participants with short (\\<= 2 years) and longer (\\>2 years) disease duration will be reported. Control of disease was defined as participants with a PASI score \\<3. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease'}, {'measure': 'Group 1, Group 2a, Group 2b, Group 2c, Group 3a and Group 3b: Percentage of Participants Who Achieve a PASI 75/90/100 Response at Weeks 20, 28, 68, 116, 164, and 220', 'timeFrame': 'Weeks 20, 28, 68, 116, 164, and 220', 'description': 'Percentage of participants who achieved PASI 75/90/100 response were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. PASI 75 responders were defined as participants with \\>= 75% improvement in PASI from baseline. PASI 90 responders were defined as participants with \\>= 90% improvement in PASI from baseline. PASI 100 responders were defined as participants with 100% improvement in PASI from baseline.'}, {'measure': 'Group 3a and Group 3b: Time to Loss of Disease Control (Absolute PASI Score >5) After Treatment Withdrawal', 'timeFrame': 'Week 68 up to Week 220', 'description': 'Time to loss of disease control (absolute PASI score \\>5) after treatment withdrawal beyond Week 68 up to Week 116 were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.'}, {'measure': 'Group 1: Percentage of Participants With an Absolute PASI Score = 0 at Weeks 12, 16, 20 and 28', 'timeFrame': 'Weeks 12, 16, 20 and 28', 'description': 'Percentage of participants with an absolute PASI score = 0 at Weeks 12, 16, 20 and 28 were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.'}, {'measure': 'Group 1, Group 2a, Group 2b, Group 2c, Group 3a, Group 3b and Group 3c: Change From Baseline (Week 0) in Dermatology Life Quality Index (DLQI) Score at Weeks 28, 68, 116, 164 and 220', 'timeFrame': 'Baseline (Week 0), Weeks 28, 68, 116, 164 and 220', 'description': "Change from baseline (Week 0) in DLQI score at Weeks 28, 68, 116, 164 and 220 will be reported. DLQI was a 10-item instrument questionnaire designed to assess the impact of the disease on a participant's quality of life. Each question was evaluated on a 4-point scale ranged from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants."}, {'measure': 'Group 1, Group 2a, Group 2b, Group 2c, Group 3a, Group 3b and Group 3c: Percentage of Participants Who Achieved a DLQI Score 0/1 and <5', 'timeFrame': 'Weeks 28, 68, 116, 164 and 220', 'description': "Percentage of participants who achieved a DLQI score 0/1 and \\<5 will be reported. DLQI was a 10-item instrument questionnaire designed to assess the impact of the disease on a participant's quality of life. Each question was evaluated on a 4-point scale ranged from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants."}, {'measure': 'Groups 1, 2a, 2b, 2c, 2d, 3a, 3b, and 3c: Percent Change From Baseline (Week 0) in Psoriasis- Affected Body Surface Area (BSA) at Weeks 12, 28, 52, 68, 80, 104, 116, 140, 164, 188, 212 and 220', 'timeFrame': 'Baseline (Week 0), Weeks 12, 28, 52, 68, 80, 104, 116, 140, 164, 188, 212 and 220', 'description': 'Change from baseline in the psoriasis affected BSA (%) at Weeks 12, 28, 52, 68, 80, 104, 116, 140, 164, 188, 212 and 220 will be reported. The percentage of the psoriasis-affected BSA percentage is a system used for assessing the severity of psoriasis. The plaque coverage is estimated using the rule of palm (1 palm of the hand = 1% BSA).'}, {'measure': 'Groups 1, 2a, 2b, 2c, 3a and 3b: Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis-Quality of Life (NAPPA-QOL) at Weeks 28, 68, 116, 164 and 220', 'timeFrame': 'Baseline (Week 0), 28, 68, 116, 164 and 220', 'description': 'Change from baseline in NAPPA-QOL at Weeks 28, 68, 116, 164 and 220 will be reported. The NAPPA was an instrument for assessing clinical and patient-reported outcomes in nail psoriasis. NAPPA-QOL was a 20-item nail-specific QoL questionnaire covering past week. Signs, stigma and everyday life were rated on a 5-point scale, ranged from 0 (no suffering) to 4 (high suffering). A global score was computed by averaging all items which ranged from 0 (no suffering) to 4 (high suffering). A decrease in NAPPA QoL score indicated improvement.'}, {'measure': 'Groups 1, 2a, 2b, 2c, 3a, and 3b: Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis- Patient Benefit Index (NAPPA-PBI) at Weeks 28, 68, 116, 164 and 220', 'timeFrame': 'Baseline (Week 0), Weeks 28, 68, 116, 164 and 220', 'description': 'Change from baseline in NAPPA-PBI at Weeks 28, 68, 116, 164 and 220 will be reported. The NAPPA was an instrument for assessing clinical and patient-reported outcomes in nail psoriasis. NAPPA-PBI was a 24-item questionnaire to assess participant-defined needs before and participant-rated benefits after treatment. The answers were given on a scale from 0 to 4, and a global score was calculated as follows: Each benefit item was multiplied with the respective importance item, and the product is divided by the sum of all importance items. The results were summed up over all items. The resulting global score ranged from 0 (no benefit) to 4 (highest possible benefit). Higher score indicated more benefit.'}, {'measure': 'Groups 1, 2a, 2b, 2c, 3a and 3b: Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis- Clinical (NAPPA-CLIN) at Weeks 28, 68, 116, 164 and 220', 'timeFrame': 'Baseline (Week 0), Weeks 28, 68, 116, 164 and 220', 'description': 'Change from baseline in NAPPA-CLIN at Weeks 28, 68, 116 164, and 220 will be reported. The NAPPA is an instrument for assessing clinical and patient-reported outcomes in nail psoriasis. NAPPA-CLIN is an instrument used by the physician to assess the least and the worst involved nail of both hands or both feet with scores ranging from 0 (no involvement) to 16 (worst involvement). A higher score indicated a worst involvement.'}, {'measure': 'Group 1, Group 2a, Group 2b, Group 2c, Group 3a and Group 3b: Change From Baseline (Week 0) in the Signs and Symptoms Aggregate Scores of the Psoriasis Symptoms and Signs Diary (PSSD) at Weeks 28, 68, 116, 164 and 220', 'timeFrame': 'Baseline (Week 0), Weeks 28, 68, 116, 164 and 220', 'description': 'Change from baseline (Week 0) in the signs and symptoms aggregate scores of the PSSD at Weeks 28, 68, 116, 164 and 220 will be reported. The PSSD was a questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a participant self-administered outcomes instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores each ranging from 0 to 100 were derived: the psoriasis symptom score and the psoriasis sign score. A higher score indicated more severe disease. A change of \\>= 40 points in PSSD symptom score or sign score, and a \\>= 3-point change in individual PSSD item scale scores will be defined as clinically meaningful change (response).'}, {'measure': 'Group 2a, Group 2b and Group 2c: Percentage of Participants Who Achieved a PSSD Sign Score = 0 at Week 68 in Participants With a PSSD Sign Score >= 1 at Week 28', 'timeFrame': 'Week 68', 'description': 'Percentage of participants who achieved a PSSD sign score = 0 at Week 68 in participants with a PSSD sign score \\>= 1 at Week 28 will be reported. The PSSD was a questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a participant self-administered outcomes instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores each ranging from 0 to 100 were derived: the psoriasis symptom score and the psoriasis sign score. A higher score indicated more severe disease. A change of \\>= 40 points in PSSD symptom score or sign score, and a \\>= 3-point change in individual PSSD item scale scores will be defined as clinically meaningful change (response).'}, {'measure': 'Group 1, Group 2a, Group 2b and Group 2c: Relationship Between Trough Serum Concentration and Efficacy or Serum Biomarker Level', 'timeFrame': 'Up to Week 80', 'description': 'The potential association between trough serum guselkumab concentration and efficacy or serum biomarker level will be analyzed by immunoassays. For the analyses the trough serum guselkumab concentration will be set into relation with the efficacy (e.g. PASI response) or with serum biomarker (e.g. serum IL-17A, IL-17F, IL-22) concentration. Guselkumab and all biomarker concentrations will be measured in the unit of picogram/milliliter (pg/mL). In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.'}, {'measure': 'Group 2a and Group 2b: Relationship Between Trough Serum Guselkumab Levels at Weeks 20, 28, 36 and 68 and Achieving PASI Score <3 at Week 68', 'timeFrame': 'Weeks 20, 28, 36, 68', 'description': 'The potential association between trough serum guselkumab levels at weeks 20, 28, 36 and 68 and achieving a PASI score \\<3 at Week 68 will be analyzed. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicated more severe disease.'}, {'measure': 'Group 2d and Group 3c: Percentage of Participants Who Were Re-Treated Due to Loss of Disease Control (PASI >5) and Regain Control of Disease (PASI <3) 24 Weeks After Start of Re-Treatment', 'timeFrame': 'Start of re-treatment up to 24 weeks', 'description': 'Percentage of participants who were re-treated due to loss of disease control (PASI \\>5) and regain control of disease (PASI \\<3) 24 Weeks after start of re-treatment will be reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to numeric score that ranged from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.'}, {'measure': 'Group 1, Group 2a, Group 2b, Group 2c, Group 2d, Group 3a, Group 3b, and Group 3c: Number of Participants With Adverse Events as a Measure of Safety and Tolerability', 'timeFrame': 'Up to Week 220', 'description': 'An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.'}, {'measure': 'Group 1, Group 2a, Group 2b, Group 2c, Group 2d, Group 3a, Group 3b and Group 3c): Number of Participants With Clinically Significant Laboratory Abnormalities', 'timeFrame': 'Week 220', 'description': 'Number of participants with laboratory abnormalities (hematology, serum chemistry and serology) were reported.'}]}, 'oversightModule': {'isUsExport': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Psoriasis']}, 'referencesModule': {'references': [{'pmid': '39083288', 'type': 'DERIVED', 'citation': 'Eyerich K, Asadullah K, Pinter A, Weisenseel P, Reich K, Paul C, Sabat R, Wolk K, Eyerich S, Lauffer F, Angsana J, Taut FJH, Kohler K, Chen Y, Sendecki J, Leung MWL, Wegner S, Personke Y, Gomez M, Kruger N, Tabori S, Schakel K. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial. JAMA Dermatol. 2024 Sep 1;160(9):953-963. doi: 10.1001/jamadermatol.2024.2463.'}, {'pmid': '34518264', 'type': 'DERIVED', 'citation': 'Eyerich K, Weisenseel P, Pinter A, Schakel K, Asadullah K, Wegner S, Munoz-Elias EJ, Bartz H, Taut FJH, Reich K. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 2021 Sep 13;11(9):e049822. doi: 10.1136/bmjopen-2021-049822.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of disease until week 68 with prolonged treatment intervals of 16 weeks (guselkumab 100 mg every 16 weeks).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Has a disease duration of plaque psoriasis of either less than or equal to (\\<=2) years or (greater than (\\>2) years calculated from date at which first symptoms \\[plaque\\] were reported by subject to date of screening visit at screening; approximately 40 percentage (%) of participants must have a disease duration \\<=2 years\n* Has moderate-to-severe plaque-psoriasis defined by a Psoriasis Area and Severity Index (PASI) score \\>10 or affected body surface area (BSA) \\>10%) and additionally a Dermatology Life Quality Index (DLQI) score \\>10 at baseline (week 0)\n* Have no signs or symptoms suggestive of active tuberculosis (TB) upon medical history and/or physical examination\n* Agrees not to receive a live virus or live bacterial vaccination during the study, or within 3 months after the last administration of study drug\n* Agrees not to receive a Bacille Calmette-Guerin (BCG) vaccination during the study, or within 12 months after the last administration of study drug\n\nExclusion Criteria:\n\n* Has previously received any therapeutic agent directly targeted to interleukin (IL) -23 (including but not limited to guselkumab, tildrakizumab \\[MK3222\\], risankizumab \\[BI-655066\\])\n* Has received any systemic immunosuppressant (for example, methotrexate, azathioprine, cyclosporine, 6-thioguanine, mercaptopurine, mycophenolate mofetil, tacrolimus, fumaric acid esters), or anakinra within 4 weeks of the first administration of study drug.\n* Tests positive for hepatitis B virus (HBV) infection or who are seropositive for antibodies to hepatitis C virus (HCV), unless they have 2 negative HCV RNA test results 6 months apart after completing antiviral treatment and prior to baseline and have a third negative HCV RNA test result at baseline\n* Has received natalizumab, belimumab, or agents that modulate B cells or T cells (e.g., rituximab, alemtuzumab, abatacept, or visilizumab) within 12 months of the first administration of study drug\n* Has received any anti - tumor necrosis factor (TNF)-α biologic therapy within 3 months before the first administration of study drug'}, 'identificationModule': {'nctId': 'NCT03818035', 'acronym': 'GUIDE', 'briefTitle': 'A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Janssen-Cilag International NV'}, 'officialTitle': 'A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies With Guselkumab in Patients With Moderate-to-Severe Plaque-Type Psoriasis', 'orgStudyIdInfo': {'id': 'CR108514'}, 'secondaryIdInfos': [{'id': '2018-001238-16', 'type': 'EUDRACT_NUMBER'}, {'id': 'CNTO1959PSO3012', 'type': 'OTHER', 'domain': 'Janssen-Cilag International NV'}, {'id': '2023-508424-34-00', 'type': 'REGISTRY', 'domain': 'EUCT number'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part 1: Guselkumab', 'description': 'Participants in group 1 (Part 1) will receive 100 milligram (mg) guselkumab subcutaneously (SC) at Weeks 0, 4, 12 and 20.', 'interventionNames': ['Drug: Guselkumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2: Guselkumab q8w and Guselkumab q16w', 'description': 'Eligible participants from Part 1 will continue to participate in Part 2. Participants (super responder \\[SRe\\]) with a Psoriasis Area and Severity Index (PASI) score = 0 at weeks 20 and 28 will be randomized to guselkumab 100 mg every 8 weeks (q8w) (group 2a) or guselkumab 100 mg q16w (group 2b), at weeks 28 to 60. Group 2b will receive placebo injection at weeks 28, 44 and 60 to keep the comparison double blind. Participants losing control of disease (PASI score \\>5) during study Part 2 (until week 60), will enter the re-treatment arm (group 2d) and receive guselkumab 100mg q8w (at re-treatment week 0), followed by administration at re-treatment-weeks 8 and 16.', 'interventionNames': ['Drug: Guselkumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2: Guselkumab q8w', 'description': 'Participants (Non SRe) in group 2c with a PASI score greater than (\\>) 0 at week 20 and/or 28 will continue to receive guselkumab 100 mg q8w until week 60.', 'interventionNames': ['Drug: Guselkumab', 'Drug: Placebo Injection']}, {'type': 'EXPERIMENTAL', 'label': 'Part 3: Guselkumab Withdrawal', 'description': 'Participants from groups 2a and 2b with a PASI score \\<3 at week 68 will be included in Part 3 (group 3a and 3b) and be withdrawn from guselkumab. Study visits will be conducted every 12 weeks until week 220 (follow-up). Participants with fluctuating disease (PASI score greater than or equal to \\[\\>=\\] 3) at week 68 or PASI \\>5 (participants losing control of disease) at any visit during part 3 after week 68 will get an opportunity to enter the re-treatment-arm (group 3c) in which participants will receive three guselkumab injections of 100 mg q8w.', 'interventionNames': ['Drug: Guselkumab']}], 'interventions': [{'name': 'Guselkumab', 'type': 'DRUG', 'otherNames': ['TREMFYA'], 'description': 'Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.', 'armGroupLabels': ['Part 1: Guselkumab', 'Part 2: Guselkumab q8w', 'Part 2: Guselkumab q8w and Guselkumab q16w', 'Part 3: Guselkumab Withdrawal']}, {'name': 'Placebo Injection', 'type': 'DRUG', 'description': 'Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.', 'armGroupLabels': ['Part 2: Guselkumab q8w']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92160', 'city': 'Antony', 'country': 'France', 'facility': "Hopital Prive d'Antony", 'geoPoint': {'lat': 48.75329, 'lon': 2.29668}}, {'zip': '89011', 'city': 'Auxerre', 'country': 'France', 'facility': "Centre Hospitalier d'Auxerre", 'geoPoint': {'lat': 47.7996, 'lon': 3.57033}}, {'zip': '51430', 'city': 'Bezanne', 'country': 'France', 'facility': 'Polyclinique Reims Bezanne - De Courlancy'}, {'zip': '72037', 'city': 'Le Mans', 'country': 'France', 'facility': 'Centre Hospitalier Le Mans', 'geoPoint': {'lat': 48.0021, 'lon': 0.20251}}, {'zip': '69437', 'city': 'Lyon', 'country': 'France', 'facility': 'Hôpital Edouard Herriot', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '13500', 'city': 'Martigues', 'country': 'France', 'facility': 'Le Bateau Blanc', 'geoPoint': {'lat': 43.40735, 'lon': 5.05526}}, {'zip': '44093', 'city': 'Nantes', 'country': 'France', 'facility': 'CHU Nantes', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '06202', 'city': 'Nice', 'country': 'France', 'facility': 'CHU de Nice Hopital de l Archet', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'zip': '76000', 'city': 'Rouen', 'country': 'France', 'facility': 'CHU Rouen', 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}, {'zip': '83041', 'city': 'Toulon', 'country': 'France', 'facility': 'HIA se Sainte-Anne - Toulon', 'geoPoint': {'lat': 43.12442, 'lon': 5.92836}}, {'zip': '31059', 'city': 'Toulouse', 'country': 'France', 'facility': 'CHU Toulouse', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '52074', 'city': 'Aachen', 'country': 'Germany', 'facility': 'Universitätsklinikum Aachen', 'geoPoint': {'lat': 50.77664, 'lon': 6.08342}}, {'zip': '86179', 'city': 'Augsburg', 'country': 'Germany', 'facility': 'DermaManagement Augsburg GmbH', 'geoPoint': {'lat': 48.37154, 'lon': 10.89851}}, {'zip': '86179', 'city': 'Augsburg', 'country': 'Germany', 'facility': 'Klinikum Augsburg', 'geoPoint': {'lat': 48.37154, 'lon': 10.89851}}, {'zip': '48455', 'city': 'Bad Bentheim', 'country': 'Germany', 'facility': 'Fachklinik Bad Bentheim', 'geoPoint': {'lat': 52.30066, 'lon': 7.15763}}, {'zip': '65812', 'city': 'Bad Soden am Taunus', 'country': 'Germany', 'facility': 'Hautmedizin Bad Soden', 'geoPoint': {'lat': 50.1408, 'lon': 8.50449}}, {'zip': '10117', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Charite CCM, Dermatologie', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '10119', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Vivantes Klinikum Im Friedrichshain', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '10783', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Rothhaar Studien GmbH', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '10789', 'city': 'Berlin', 'country': 'Germany', 'facility': 'ISA - Interdisciplinary Study Association GmbH', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '12459', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Hautarztpraxis', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '13055', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Hautarztpraxis Dr.Wildfeuer', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '13597', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Hautarztpraxis', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '13597', 'city': 'Berlin', 'country': 'Germany', 'facility': "Praxis 'Haut Pur'", 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '33647', 'city': 'Bielefeld', 'country': 'Germany', 'facility': 'Klinikum Bielefeld Rosenhoehe', 'geoPoint': {'lat': 52.03333, 'lon': 8.53333}}, {'zip': '44791', 'city': 'Bochum', 'country': 'Germany', 'facility': 'Katholisches Klinikum Bochum gGmbH', 'geoPoint': {'lat': 51.48165, 'lon': 7.21648}}, {'zip': '44793', 'city': 'Bochum', 'country': 'Germany', 'facility': 'Niesmann & Othlinghaus GbR', 'geoPoint': {'lat': 51.48165, 'lon': 7.21648}}, {'zip': '53111', 'city': 'Bonn', 'country': 'Germany', 'facility': 'MVZ Dermatologisches Zentrum Bonn GmbH', 'geoPoint': {'lat': 50.73438, 'lon': 7.09549}}, {'zip': '53127', 'city': 'Bonn', 'country': 'Germany', 'facility': 'Universitatsklinikum Bonn', 'geoPoint': {'lat': 50.73438, 'lon': 7.09549}}, {'zip': '04552', 'city': 'Borna', 'country': 'Germany', 'facility': 'Hautarztpraxis', 'geoPoint': {'lat': 51.12416, 'lon': 12.49639}}, {'zip': '49565', 'city': 'Bramsche', 'country': 'Germany', 'facility': 'Hautarztpraxis', 'geoPoint': {'lat': 52.40881, 'lon': 7.97288}}, {'zip': '28779', 'city': 'Bremen', 'country': 'Germany', 'facility': 'Derma Nord', 'geoPoint': {'lat': 53.07582, 'lon': 8.80717}}, {'zip': '50937', 'city': 'Cologne', 'country': 'Germany', 'facility': 'Universitaetsklinikum Koeln', 'geoPoint': {'lat': 50.93333, 'lon': 6.95}}, {'zip': '64283', 'city': 'Darmstadt', 'country': 'Germany', 'facility': 'Klinikum Darmstadt GmbH - Hautklinik', 'geoPoint': {'lat': 49.87167, 'lon': 8.65027}}, {'zip': '64283', 'city': 'Darmstadt', 'country': 'Germany', 'facility': 'Rosenpark Research GmbH', 'geoPoint': {'lat': 49.87167, 'lon': 8.65027}}, {'zip': '01069', 'city': 'Dresden', 'country': 'Germany', 'facility': 'Klinische Forschung Dresden GmbH', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '01097', 'city': 'Dresden', 'country': 'Germany', 'facility': 'Praxis für Dermatologie und Venerologie', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '01307', 'city': 'Dresden', 'country': 'Germany', 'facility': 'University Hospital Dresden', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '48249', 'city': 'Dülmen', 'country': 'Germany', 'facility': 'Pro Derma', 'geoPoint': {'lat': 51.83149, 'lon': 7.28075}}, {'zip': '40212', 'city': 'Düsseldorf', 'country': 'Germany', 'facility': 'Privatpraxis Dr. Hilton & Partner', 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}}, {'zip': '40225', 'city': 'Düsseldorf', 'country': 'Germany', 'facility': 'Universitatsklinikum Dusseldorf', 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}}, {'zip': '91054', 'city': 'Erlangen', 'country': 'Germany', 'facility': 'Universitaetsklinik Erlangen', 'geoPoint': {'lat': 49.59099, 'lon': 11.00783}}, {'zip': '45122', 'city': 'Essen', 'country': 'Germany', 'facility': 'Universitaetsklinikum Essen', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '60590', 'city': 'Frankfurt am Main', 'country': 'Germany', 'facility': 'Universitatsklinikum Frankfurt', 'geoPoint': {'lat': 50.11552, 'lon': 8.68417}}, {'zip': '79104', 'city': 'Freiburg im Breisgau', 'country': 'Germany', 'facility': 'Universitatsklinikum Freiburg', 'geoPoint': {'lat': 47.9959, 'lon': 7.85222}}, {'zip': '88045', 'city': 'Friedrichshafen', 'country': 'Germany', 'facility': 'Derma-Study-Center Friedrichshafen GmbH', 'geoPoint': {'lat': 47.65689, 'lon': 9.47554}}, {'zip': '07548', 'city': 'Gera', 'country': 'Germany', 'facility': 'SRH Waldklinikum Gera GmbH', 'geoPoint': {'lat': 50.88029, 'lon': 12.08187}}, {'zip': '35390', 'city': 'Giessen', 'country': 'Germany', 'facility': 'Hautarztpraxis Brau/Groß', 'geoPoint': {'lat': 50.58727, 'lon': 8.67554}}, {'zip': '37075', 'city': 'Göttingen', 'country': 'Germany', 'facility': 'Universitatsmedizin Gottingen', 'geoPoint': {'lat': 51.53443, 'lon': 9.93228}}, {'zip': '20246', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Universitaetsklinik Hamburg-Eppendorf', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '20253', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Klinische Forschung Hamburg', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '20354', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Dermatologikum Hamburg Gmbh', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '20537', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'SCIderm GmbH', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '22391', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'MensingDerma research GmbH', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '63450', 'city': 'Hanau', 'country': 'Germany', 'facility': 'Die Hautklinik Hanau', 'geoPoint': {'lat': 50.13423, 'lon': 8.91418}}, {'zip': '69115', 'city': 'Heidelberg', 'country': 'Germany', 'facility': 'Haut- und Laserzentrum Heidelberg', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'zip': '69120', 'city': 'Heidelberg', 'country': 'Germany', 'facility': 'Universitaetsklinikum Heidelberg', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'zip': '49477', 'city': 'Ibbenbueren', 'country': 'Germany', 'facility': 'Hautarztpraxis Offers/Adamini', 'geoPoint': {'lat': 52.27964, 'lon': 7.71457}}, {'zip': '07745', 'city': 'Jena', 'country': 'Germany', 'facility': 'Universitatsklinikum Jena', 'geoPoint': {'lat': 50.92878, 'lon': 11.5899}}, {'zip': '24105', 'city': 'Kiel', 'country': 'Germany', 'facility': 'Universitatsklinikum Schleswig Holstein Kiel', 'geoPoint': {'lat': 54.32133, 'lon': 10.13489}}, {'zip': '24148', 'city': 'Kiel', 'country': 'Germany', 'facility': 'MVZ DermaKiel GmbH', 'geoPoint': {'lat': 54.32133, 'lon': 10.13489}}, {'zip': '89129', 'city': 'Langenau', 'country': 'Germany', 'facility': 'Praxis Dr. med. Beate Schwarz - Germany', 'geoPoint': {'lat': 48.49616, 'lon': 10.11849}}, {'zip': '04103', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Universitatsklinikum Leipzig AOR', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '49809', 'city': 'Lingen', 'country': 'Germany', 'facility': 'Hautarztpraxis', 'geoPoint': {'lat': 52.52143, 'lon': 7.31845}}, {'zip': '39120', 'city': 'Magdeburg', 'country': 'Germany', 'facility': 'Otto Von Guericke Universität Magdeburg', 'geoPoint': {'lat': 52.13129, 'lon': 11.63189}}, {'zip': '15831', 'city': 'Mahlow', 'country': 'Germany', 'facility': 'Gemeinschaftspraxis Scholz/Sebastian/Schilling', 'geoPoint': {'lat': 52.36017, 'lon': 13.40954}}, {'zip': '55128', 'city': 'Mainz', 'country': 'Germany', 'facility': 'Hautarztzentrum am MDZ', 'geoPoint': {'lat': 49.98185, 'lon': 8.28008}}, {'zip': '55131', 'city': 'Mainz', 'country': 'Germany', 'facility': 'Universitaetsmedizin Mainz', 'geoPoint': {'lat': 49.98185, 'lon': 8.28008}}, {'zip': '68167', 'city': 'Mannheim', 'country': 'Germany', 'facility': 'Universitaetsklinikum Mannheim', 'geoPoint': {'lat': 49.4891, 'lon': 8.46694}}, {'zip': '87700', 'city': 'Memmingen', 'country': 'Germany', 'facility': 'Hautarztpraxis', 'geoPoint': {'lat': 47.98372, 'lon': 10.18527}}, {'zip': '41061', 'city': 'Mönchengladbach', 'country': 'Germany', 'facility': 'Zentderma BAG Dres. Ostendorf - Bohm - Jo GbR', 'geoPoint': {'lat': 51.18539, 'lon': 6.44172}}, {'zip': '80802', 'city': 'München', 'country': 'Germany', 'facility': 'Technische Universitaet Muenchen', 'geoPoint': {'lat': 51.60698, 'lon': 13.31243}}, {'zip': '48149', 'city': 'Münster', 'country': 'Germany', 'facility': 'Universitaetsklinikum Muenster', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'zip': '26133', 'city': 'Oldenburg', 'country': 'Germany', 'facility': 'Klinikum Oldenburg', 'geoPoint': {'lat': 53.14039, 'lon': 8.21479}}, {'zip': '49074', 'city': 'Osnabrück', 'country': 'Germany', 'facility': 'Klinische Forschung Osnabrück', 'geoPoint': {'lat': 52.27264, 'lon': 8.0498}}, {'zip': '14467', 'city': 'Potsdam', 'country': 'Germany', 'facility': 'Hautarztpraxis', 'geoPoint': {'lat': 52.39886, 'lon': 13.06566}}, {'zip': '06484', 'city': 'Quedlinburg', 'country': 'Germany', 'facility': 'Harzklinikum Dorothea Christiane Erxleben GmbH - Germnay', 'geoPoint': {'lat': 51.78843, 'lon': 11.15006}}, {'zip': '93053', 'city': 'Regensburg', 'country': 'Germany', 'facility': 'Universitaetsklinikum Regensburg', 'geoPoint': {'lat': 49.01513, 'lon': 12.10161}}, {'zip': '42897', 'city': 'Remscheid', 'country': 'Germany', 'facility': 'Hautarztpraxis Mortazawi', 'geoPoint': {'lat': 51.17983, 'lon': 7.1925}}, {'zip': '19055', 'city': 'Schwerin', 'country': 'Germany', 'facility': 'Klinische Forschung Schwerin GmbH', 'geoPoint': {'lat': 53.62937, 'lon': 11.41316}}, {'zip': '56242', 'city': 'Selters', 'country': 'Germany', 'facility': 'Company for Medical Study & Service Selters', 'geoPoint': {'lat': 50.51681, 'lon': 8.28953}}, {'zip': '70178', 'city': 'Stuttgart', 'country': 'Germany', 'facility': 'Hautarztpraxis Dr. Leitz & Kollegen', 'geoPoint': {'lat': 48.78232, 'lon': 9.17702}}, {'zip': '70499', 'city': 'Stuttgart', 'country': 'Germany', 'facility': 'Hautarztpraxis am Loewenmarkt', 'geoPoint': {'lat': 48.78232, 'lon': 9.17702}}, {'zip': '72076', 'city': 'Tübingen', 'country': 'Germany', 'facility': 'Universitatsklinikum Tubingen', 'geoPoint': {'lat': 48.52266, 'lon': 9.05222}}, {'zip': '89081', 'city': 'Ulm', 'country': 'Germany', 'facility': 'Universitatsklinikum Ulm', 'geoPoint': {'lat': 48.39841, 'lon': 9.99155}}, {'zip': '49377', 'city': 'Vechta', 'country': 'Germany', 'facility': 'Hautarztpraxis Kock', 'geoPoint': {'lat': 52.72632, 'lon': 8.28598}}, {'zip': '58453', 'city': 'Witten', 'country': 'Germany', 'facility': 'Centrovital', 'geoPoint': {'lat': 51.44362, 'lon': 7.35258}}, {'zip': '42283', 'city': 'Wuppertal', 'country': 'Germany', 'facility': 'HELIOS Klinikum Wuppertal GmbH', 'geoPoint': {'lat': 51.25627, 'lon': 7.14816}}, {'zip': '42287', 'city': 'Wuppertal', 'country': 'Germany', 'facility': 'CentroDerm GmbH', 'geoPoint': {'lat': 51.25627, 'lon': 7.14816}}, {'zip': '97080', 'city': 'Würzburg', 'country': 'Germany', 'facility': 'Universitatsklinikum Wurzburg', 'geoPoint': {'lat': 49.79391, 'lon': 9.95121}}], 'overallOfficials': [{'name': 'Janssen-Cilag International NV Clinical Trial', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Janssen-Cilag International NV'}]}, 'ipdSharingStatementModule': {'url': 'https://www.janssen.com/clinical-trials/transparency', 'ipdSharing': 'YES', 'description': 'The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency.\n\nAs noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Janssen-Cilag International NV', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}